308 related articles for article (PubMed ID: 14735686)
1. Alternating doublets: establishing the optimal multifractionated dosing schedule to administer docetaxel, cisplatin, gemcitabine, and vinorelbine in combination.
Lokich J; Anderson N; Coco F
Cancer Invest; 2003; 21(6):830-6. PubMed ID: 14735686
[TBL] [Abstract][Full Text] [Related]
2. Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma: Phase II trials of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Burris HA; Billings FT; Bradof JE; Baker M; Greco FA
Cancer; 2001 Nov; 92(9):2391-8. PubMed ID: 11745295
[TBL] [Abstract][Full Text] [Related]
3. The multifractionated, twice-weekly dose schedule for a three-drug chemotherapy regimen: a phase I-II study of paclitaxel, cisplatin, and vinorelbine.
Lokich JJ; Anderson N; Bern M; Coco F; Dow E
Cancer; 1999 Jan; 85(2):499-503. PubMed ID: 10023721
[TBL] [Abstract][Full Text] [Related]
4. Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-small cell lung cancer: A multicenter randomized phase II trial of the Hellenic Oncology Research Group (HORG).
Kotsakis A; Kentepozidis N; Emmanouilidis Ch; Polyzos A; Agelidou A; Vaslamatzis M; Chandrinos V; Agelaki S; Vamvakas L; Kalbakis K; Katsaounis P; Stoltidis D; Nintos G; Hatzidaki D; Vetsika EK; Mavroudis D; Georgoulias V
Lung Cancer; 2015 Apr; 88(1):57-62. PubMed ID: 25662596
[TBL] [Abstract][Full Text] [Related]
5. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial.
Georgoulias V; Ardavanis A; Tsiafaki X; Agelidou A; Mixalopoulou P; Anagnostopoulou O; Ziotopoulos P; Toubis M; Syrigos K; Samaras N; Polyzos A; Christou A; Kakolyris S; Kouroussis C; Androulakis N; Samonis G; Chatzidaki D
J Clin Oncol; 2005 May; 23(13):2937-45. PubMed ID: 15728228
[TBL] [Abstract][Full Text] [Related]
6. Phase II randomized multicenter study evaluating a treatment regimen alternating docetaxel and cisplatin-vinorelbine with a cisplatin-vinorelbine control group in patients with stage IV non-small-cell lung cancer: GFPC 97.01 study.
Pérol M; Léna H; Thomas P; Robinet G; Fournel P; Coste E; Belleguic C; Le Caer H; Blanchon F; Vergnenègre A; Vernejoux JM; Schuller-Lebeau MP; Pham E
Ann Oncol; 2002 May; 13(5):742-7. PubMed ID: 12075743
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial.
Alberola V; Camps C; Provencio M; Isla D; Rosell R; Vadell C; Bover I; Ruiz-Casado A; Azagra P; Jiménez U; González-Larriba JL; Diz P; Cardenal F; Artal A; Carrato A; Morales S; Sanchez JJ; de las Peñas R; Felip E; López-Vivanco G;
J Clin Oncol; 2003 Sep; 21(17):3207-13. PubMed ID: 12947054
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin.
Pujol JL; Breton JL; Gervais R; Rebattu P; Depierre A; Morère JF; Milleron B; Debieuvre D; Castéra D; Souquet PJ; Moro-Sibilot D; Lemarié E; Kessler R; Janicot H; Braun D; Spaeth D; Quantin X; Clary C
Ann Oncol; 2005 Apr; 16(4):602-10. PubMed ID: 15741225
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
Cobo Dols M; Villar Chamorro E; Alés Díaz I; Gil Calle S; Alcalde García J; Gutiérrez Calderón V; Carabantes Ocón F; Montesa Pino A; Bretón García JJ; Benavides Orgaz M
Clin Transl Oncol; 2006 Oct; 8(10):742-9. PubMed ID: 17074673
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial.
Binder D; Schweisfurth H; Grah C; Schäper C; Temmesfeld-Wollbrück B; Siebert G; Suttorp N; Beinert T
Cancer Chemother Pharmacol; 2007 Jun; 60(1):143-50. PubMed ID: 17031643
[TBL] [Abstract][Full Text] [Related]
11. An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic co-operative Oncology Group.
Pectasides D; Kalofonos HP; Samantas E; Nicolaides C; Papacostas P; Onyenadum A; Visvikis A; Skarlos D; Fountzilas G
Anticancer Res; 2001; 21(4B):3005-10. PubMed ID: 11712802
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary toxicity in patients treated with gemcitabine plus vinorelbine or docetaxel for advanced non-small cell lung cancer: outcome data on a randomized phase II study.
Esteban E; Villanueva N; Muñiz I; Fernández Y; Fra J; Luque M; Jiménez P; Llorente B; Capelan M; Vieitez JM; Estrada E; Buesa JM; Jiménez-Lacave A
Invest New Drugs; 2008 Feb; 26(1):67-74. PubMed ID: 17805486
[TBL] [Abstract][Full Text] [Related]
13. Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancer.
Clark JI; Kancharla K; Qamar R; Fisher S; Hantel A; Panganiban J; Millbrandt L; Albain KS
Lung Cancer; 2001 Nov; 34(2):271-7. PubMed ID: 11679186
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of alternating chemotherapy regimens for advanced non-small cell lung cancer.
Stewart DJ; Tomiak E; Shamji FM; Maziak DE; MacLeod P
Lung Cancer; 2004 May; 44(2):241-9. PubMed ID: 15084389
[TBL] [Abstract][Full Text] [Related]
15. Same-day pegfilgrastim and chemotherapy.
Lokich J
Cancer Invest; 2005; 23(7):573-6. PubMed ID: 16305982
[TBL] [Abstract][Full Text] [Related]
16. A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer.
Grossi F; de Marinis F; Gebbia V; Riccardi F; Caffo O; Gamucci T; Ferraù F; Nardi M; Moscetti L; Boni L; Dondi D; Galligioni E
Cancer Chemother Pharmacol; 2012 Feb; 69(2):369-75. PubMed ID: 21833588
[TBL] [Abstract][Full Text] [Related]
17. Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer.
Martoni A; Marino A; Sperandi F; Giaquinta S; Di Fabio F; Melotti B; Guaraldi M; Palomba G; Preti P; Petralia A; Artioli F; Picece V; Farris A; Mantovani L
Eur J Cancer; 2005 Jan; 41(1):81-92. PubMed ID: 15617993
[TBL] [Abstract][Full Text] [Related]
18. Biweekly triplet chemotherapy with gemcitabine, cisplatin and vinorelbine for advanced chemotherapy naïve non-small cell lung cancer.
Keskin S; Tas F; Ekenel M; Kilic L; Sen F; Yildiz I; Karabulut S; Ciftci R; Vatansever S
Tumori; 2013; 99(4):463-8. PubMed ID: 24326833
[TBL] [Abstract][Full Text] [Related]
19. Sequential chemotherapy of cisplatin and vinorelbine followed by paclitaxel and gemcitabine in advanced non-small-cell lung cancer. A single institution phase II study.
Dongiovanni D; Fissore C; Berruti A; Buffoni L; Addeo A; Barone C; Polimeni MA; Ottaviani D; Bertetto O; Dongiovanni V
Lung Cancer; 2005 Feb; 47(2):269-75. PubMed ID: 15639726
[TBL] [Abstract][Full Text] [Related]
20. Non-platinum based combination chemotherapy: phase I and II trials of docetaxel plus gemcitabine, vinorelbine, or irinotecan.
Rigas JR
Semin Oncol; 2001 Jun; 28(3 Suppl 9):15-20. PubMed ID: 11441410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
